Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx is expected to see a return to growth in both its US and international markets in the back half of 2026, with double-digit growth exiting the year. The company has implemented cost restructuring initiatives resulting in improved gross margins and decreased operating expenses, and the completion of enrollment in the AeriSeal Convert II trial in 2027 may provide further growth potential in the future. However, risks such as clinical/regulatory, financial, and market share remain.

Bears say

Pulmonx is facing a challenging outlook due to disruptions in the U.S. market and delays in registration renewal in China, leading to a decline in revenue and weak financial performance in the first quarter. Despite management's reassurance and refinancing activities strengthening the balance sheet, a cautious approach towards revenue guidance for the coming years shows a lack of confidence in near-term growth potential. Risks such as clinical and regulatory, partnership and financial, and commercial risks, as well as challenges in maintaining market share, present significant hurdles for the company's long-term success.

Pulmonx (LUNG) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 6 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.